Country for PR: United States
Contributor: PR Newswire New York
Thursday, May 28 2020 - 15:30
CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement for the Supply of Lipid Excipients to be used in Moderna's Vaccine (mRNA-1273) Against the Novel Coronavirus SARS-CoV-2
LUXEMBOURG, May 28, 2020 /PRNewswire-AsiaNet/ --

CordenPharma ( 
), a full-service Contract Development & Manufacturing Organization (CDMO) for 
the supply of APIs, Drug Products & Pharmaceutical Packaging, announces the 
signing of an amendment to their existing manufacturing agreement with Moderna, 
) (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger 
RNA (mRNA) therapeutics and vaccines to create a new generation of 
transformative medicines for patients. The extension enables CordenPharma to 
manufacture large-scale volumes of Moderna's lipid excipients to be used in the 
manufacture of Moderna's vaccine candidate (mRNA-1273) against the novel 
coronavirus (SARS-CoV-2).

Logo -

Under the terms of the agreement, the companies will further extend their 
supply relationship by expanding the manufacturing agreement originally signed 
in 2016 between Moderna and CordenPharma Switzerland ( 
). The amended agreement now includes CordenPharma Chenôve ( 
) (FR) and CordenPharma Colorado ( 
) (US) for the manufacture of larger-scale volumes of lipids, while continuing 
to draw upon CordenPharma Switzerland's long-standing reputation as a leader in 
specialized lipid manufacturing ( 
). The expanded agreement will begin immediately in order to rapidly meet 
Moderna's increasing demand over the upcoming months, with an emphasis on 
securing their future long-term supply.

Juan Andres, Moderna's Chief Technical Operations and Quality Officer, 
comments, "We are pleased to extend our agreement with CordenPharma. This 
expansion will increase supply of lipid excipients used to manufacture our mRNA 
products. We appreciate CordenPharma's global presence and CDMO expertise as we 
scale manufacturing of mRNA-1273."

Dr. Michael Quirmbach, CordenPharma's President & CEO comments, "We are 
thrilled to extend our long-term agreement to help support Moderna by 
leveraging our strong global network of GMP manufacturing facilities across 
Europe and the US to supply the immediate need of lipid excipients for their 
coronavirus vaccine. We are hopeful Moderna's technology represents a positive 
impact for people suffering from COVID-19 across the globe, and we are honored 
to contribute to the industry as a whole."

About CordenPharma

CordenPharma, the global pharmaceutical manufacturing platform of ICIG, is a 
full-service Contract Development & Manufacturing Organization for APIs, Drug 
Products, and Packaging. Through cGMP facilities across Europe and the US 
organized under four Technology Platforms – Peptides, Lipids & Carbohydrates, 
Injectables, Highly Potent & Oncology, and Small Molecules – CordenPharma 
experts translate complex projects at any stage of development into high-value 

Contact us ( 
) or visit ( 

Source – CordenPharma 

CONTACT: CordenPharma Media,